

Research - Base for

Science...

Test Procedure:

It is scientifically confirmed that the human carrier protein albumin is blocked in its functions due to the presence of cancer .

Based on this we developed a routine test for the early detection of cancer.

The test is carried out by sampling 5 ml blood from a patient. Afterwards, the serum is separated and admixed with reporter molecules to determine the efficiency of transport parameters of albumin. The results, give us information about functionality or disturbances of the protein.

Thus, it is possible to make a conclusion due to the presence of cancer in the human organism independent of any localization.

Conditions for the Analysis:

For a qualified analysis it is required:

- 3-5 ml blood stored at 8°C, within 24 hours after sampling attained to MedInnovation GmbH for analysis or pure (centrifuged) serum within 4 days
- no use of blood collection systems with anticoagulant (except EDTA) and if possible no vacuum system

The early recognition of cancer plays the most important role for the successful treatment of the disease.

About Us:

The research of the alteration of blood proteins conformation is our primary business area. Main efforts are focused on the blood protein albumin, during the development of cancer. After a long and intensive research, we have succeeded in developing a novel analysis technology based on the electron spin resonance spectroscopy (ESR-spectroscopy). The method named:

MMS-technology (mobility of molecular structure)

was patented in 2001. Now for the first time a reliable laboratory routine test for early detection of cancer is available. This technology is qualified for screening, therapy monitoring and relapse control.

Our Services:

Based on this technology we offer the following performances to our customers:

- **simple and fast analysis** of blood samples
- **consultation and diagnoses** in close co-operation with the attending doctor
- **screening** (risk groups, suspected cases)
- **therapy monitoring** (pursuit of the therapy effect)
- **relapse control** (early detection of a recidivism)
- **determination of transport and detoxification properties** features of the albumin

History:

The background for the invention and the today's research activity of **MedInnovation GmbH** was the reactor catastrophe in Tschernobyl in 1986.

Numerous scientists analyze the effect of this disaster on the health of the population. A change at the blood protein albumin was identified without being able to interpret. For the first time scientists of **MedInnovation GmbH** succeeded to enable an accurate determination of transport properties of albumin in scope of a simple laboratory test.

Thus, we have developed a reliable test procedure which is specific to cancer and shows a malignant process much earlier than conventional tumor marker or image based methods do.

Our Motivation:

Cancer is one of the most common cause of death in 2004. It accounted for 7.4 million death, that are 13% of all deaths worldwide. More than 70% of all cancer deaths occurred in low- and middle-income countries. Deaths from cancer worldwide are projected to continue rising, with an estimation of 12 million deaths in 2030.

One of the reasons is the late detection of this disease. Therefore we developed a reliable procedure, which detects cancer at an early stage, independently of type or localization.

Your Advantages


- early cancer detection
- high reliability of the results (specificity > 94 %, sensitivity > 89 %, according to latest clinical studies)
- reliability of the test is independent from the type of cancer and its localization
- the test shows fast and reliably the effect of the therapy and its success
- possibility for the differentiation of malignant and non-malignant processes
- Advance in Know-how and technology (permanent actualization of the procedure based on newest research results)

We analyze the blood protein


albumin

Its physiological functions are:

- maintenance of the colloid osmotic pressure



- transport of
 - fatty acids (cell nutrients)
 - medical drugs
 - biomarkers and mediators (chemical messengers which regulate and block molecular processes)



- removal of toxins and hydrophobic metabolites (the „garbage“ of the energy production inside the cell)

We are:

MedInnovation GmbH is a young and innovative company for biotechnology and medical engineering which was established in 1999.

You still have any questions?

Please do not hesitate to contact us.



ESR - Laboratory: Office:
Freiheitstr. 124-126 Nonnendammallee 42-43
D-15745 Wildau D-13599 Berlin

contact person:

Mrs. Kerstin Schnurr PhD

+ 49 33 75 / 21 30 00

+ 49 33 75 / 21 30 33

info@medinnovation.de
www.medinnovation.de

„Our **MMS**-test determines the physiological function of albumin and diagnoses pathological changes which are specific to cancer.“



Research is Future...

MMS-laboratory test

for

- Early diagnosis of cancer -
- Therapy monitoring -
- Relapse control -